Eli Lilly and Nvidia have launched a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in drug discovery.
The lab brings together Lilly’s world-leading expertise in discovering, developing and manufacturing medicines with Nvidia’s leadership in AI, accelerated computing and AI infrastructure. The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new lab.
Based in the San Francisco Bay Area, the lab will co-locate Lilly domain experts in biology, science and medicine with top AI model builders and engineers from Nvidia, allowing them to work side by side to generate large-scale data and build powerful AI models that can accelerate medicine development, using Nvidia’s proprietary BioNeMo as the critical platform. The collaboration will initially focus on creating a continuous learning system that tightly connects Lilly’s agentic wet labs with computational dry labs, enabling 24/7 AI-assisted experimentation to support biologists and chemists.
“Nvidia and Lilly are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made,” said Jensen Huang, founder and CEO of Nvidia.